Annual CFF
$23.69 M
+$14.31 M+152.58%
December 31, 2023
Summary
- As of February 8, 2025, ONCY annual cash flow from financing activities is $23.69 million, with the most recent change of +$14.31 million (+152.58%) on December 31, 2023.
- During the last 3 years, ONCY annual CFF has fallen by -$5.99 million (-20.18%).
- ONCY annual CFF is now -27.36% below its all-time high of $32.62 million, reached on December 31, 2009.
Performance
ONCY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
N/A
September 30, 2024
Summary
- ONCY quarterly cash flow from financing activities is not available.
Performance
ONCY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
N/A
September 30, 2024
Summary
- ONCY TTM cash flow from financing activities is not available.
Performance
ONCY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ONCY Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +152.6% | - | - |
3 y3 years | -20.2% | - | - |
5 y5 years | +130.9% | - | - |
ONCY Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -10.0% | +152.6% | ||||
5 y | 5-year | -20.2% | +152.6% | ||||
alltime | all time | -27.4% | >+9999.0% |
Oncolytics Biotech Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2023 | $23.69 M(+152.6%) | $1.15 M(-92.7%) | $23.69 M(-12.5%) |
Sep 2023 | - | $15.88 M(+473.8%) | $27.07 M(+125.6%) |
Jun 2023 | - | $2.77 M(-29.0%) | $12.00 M(+28.7%) |
Mar 2023 | - | $3.90 M(-14.0%) | $9.32 M(-0.6%) |
Dec 2022 | $9.38 M(-64.4%) | $4.53 M(+462.2%) | $9.38 M(+90.3%) |
Sep 2022 | - | $805.70 K(+799.2%) | $4.93 M(+45.5%) |
Jun 2022 | - | $89.60 K(-97.7%) | $3.39 M(-67.5%) |
Mar 2022 | - | $3.96 M(+4895.3%) | $10.43 M(-60.4%) |
Dec 2021 | $26.33 M(-11.3%) | $79.20 K(-110.8%) | $26.33 M(-24.1%) |
Sep 2021 | - | -$736.10 K(-110.3%) | $34.68 M(-10.5%) |
Jun 2021 | - | $7.13 M(-64.1%) | $38.75 M(+7.8%) |
Mar 2021 | - | $19.86 M(+135.7%) | $35.94 M(+21.1%) |
Dec 2020 | $29.68 M(+87.5%) | $8.42 M(+152.7%) | $29.68 M(+4.8%) |
Sep 2020 | - | $3.33 M(-22.9%) | $28.33 M(-0.4%) |
Jun 2020 | - | $4.32 M(-68.2%) | $28.44 M(+7.8%) |
Mar 2020 | - | $13.61 M(+92.4%) | $26.37 M(+66.6%) |
Dec 2019 | $15.83 M(+54.3%) | $7.07 M(+105.8%) | $15.83 M(+60.4%) |
Sep 2019 | - | $3.44 M(+52.1%) | $9.87 M(+35.8%) |
Jun 2019 | - | $2.26 M(-26.3%) | $7.27 M(-43.7%) |
Mar 2019 | - | $3.07 M(+176.2%) | $12.92 M(+25.9%) |
Dec 2018 | $10.26 M(+3.8%) | $1.11 M(+33.0%) | $10.26 M(+8.4%) |
Sep 2018 | - | $834.30 K(-89.4%) | $9.46 M(-4.1%) |
Jun 2018 | - | $7.91 M(+1819.0%) | $9.86 M(-4.3%) |
Mar 2018 | - | $412.00 K(+32.3%) | $10.31 M(+4.2%) |
Dec 2017 | $9.89 M(+1269.3%) | $311.50 K(-74.8%) | $9.89 M(+2.5%) |
Sep 2017 | - | $1.23 M(-85.2%) | $9.64 M(+12.3%) |
Jun 2017 | - | $8.35 M(<-9900.0%) | $8.59 M(+991.0%) |
Mar 2017 | - | -$7900.00(-111.6%) | $787.30 K(+9.1%) |
Dec 2016 | $722.00 K(-96.1%) | $68.30 K(-62.1%) | $721.90 K(-38.9%) |
Sep 2016 | - | $180.40 K(-67.0%) | $1.18 M(+5927.6%) |
Jun 2016 | - | $546.50 K(-845.6%) | $19.60 K(-99.6%) |
Mar 2016 | - | -$73.30 K(-113.9%) | $5.09 M(-72.5%) |
Dec 2015 | $18.54 M(+126.3%) | $527.80 K(-153.8%) | $18.54 M(-8.7%) |
Sep 2015 | - | -$981.40 K(-117.5%) | $20.30 M(-14.7%) |
Jun 2015 | - | $5.62 M(-58.0%) | $23.81 M(+16.2%) |
Mar 2015 | - | $13.38 M(+484.4%) | $20.49 M(+150.1%) |
Dec 2014 | $8.19 M(-72.2%) | $2.29 M(-9.2%) | $8.19 M(+31.4%) |
Sep 2014 | - | $2.52 M(+9.3%) | $6.23 M(+90.9%) |
Jun 2014 | - | $2.31 M(+113.8%) | $3.26 M(+533.1%) |
Mar 2014 | - | $1.08 M(+226.8%) | $515.70 K(-98.3%) |
Dec 2013 | $29.52 M(+41.6%) | $329.90 K(-173.6%) | $29.52 M(+1.1%) |
Sep 2013 | - | -$448.50 K(+1.1%) | $29.21 M(-2.8%) |
Jun 2013 | - | -$443.80 K(-101.5%) | $30.05 M(-2.2%) |
Mar 2013 | - | $30.08 M(>+9900.0%) | $30.71 M(+47.3%) |
Dec 2012 | $20.85 M(+39.1%) | $19.40 K(-95.0%) | $20.85 M(+0.7%) |
Sep 2012 | - | $388.80 K(+74.5%) | $20.72 M(+2.5%) |
Jun 2012 | - | $222.80 K(-98.9%) | $20.21 M(-0.4%) |
Mar 2012 | - | $20.22 M(<-9900.0%) | $20.29 M(+35.4%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2011 | $14.99 M(-43.3%) | -$115.90 K(-2.7%) | $14.99 M(-63.9%) |
Sep 2011 | - | -$119.10 K(-138.9%) | $41.51 M(-0.3%) |
Jun 2011 | - | $305.80 K(-98.0%) | $41.63 M(+0.6%) |
Mar 2011 | - | $14.92 M(-43.5%) | $41.38 M(+56.4%) |
Dec 2010 | $26.46 M(-18.9%) | $26.40 M(>+9900.0%) | $26.46 M(+6.6%) |
Sep 2010 | - | $8000.00(-84.8%) | $24.82 M(-2.7%) |
Jun 2010 | - | $52.50 K(>+9900.0%) | $25.50 M(-21.8%) |
Mar 2010 | - | $0.00(-100.0%) | $32.60 M(-0.1%) |
Dec 2009 | $32.62 M(+900.2%) | $24.75 M(+3462.9%) | $32.62 M(+193.2%) |
Sep 2009 | - | $694.80 K(-90.3%) | $11.13 M(+6.7%) |
Jun 2009 | - | $7.15 M(>+9900.0%) | $10.43 M(+218.2%) |
Mar 2009 | - | $17.10 K(-99.5%) | $3.28 M(+0.5%) |
Dec 2008 | $3.26 M(-71.2%) | $3.26 M(>+9900.0%) | $3.26 M(-1647.1%) |
Sep 2008 | - | $0.00(0.0%) | -$210.80 K(-162.3%) |
Jun 2008 | - | $0.00(0.0%) | $338.20 K(-67.2%) |
Mar 2008 | - | $0.00(-100.0%) | $1.03 M(-90.9%) |
Dec 2007 | $11.33 M(+5224.5%) | -$210.80 K(-138.4%) | $11.33 M(-2.7%) |
Sep 2007 | - | $549.00 K(-20.8%) | $11.64 M(+4.2%) |
Jun 2007 | - | $693.30 K(-93.3%) | $11.17 M(+6.2%) |
Mar 2007 | - | $10.30 M(>+9900.0%) | $10.51 M(+4839.8%) |
Dec 2006 | $212.80 K(-98.6%) | $99.10 K(+30.7%) | $212.80 K(-98.3%) |
Sep 2006 | - | $75.80 K(+100.0%) | $12.81 M(-0.6%) |
Jun 2006 | - | $37.90 K(>+9900.0%) | $12.89 M(-0.9%) |
Mar 2006 | - | $0.00(-100.0%) | $13.00 M(-16.2%) |
Dec 2005 | $15.51 M(-14.3%) | $12.69 M(+7963.2%) | $15.51 M(+49.7%) |
Sep 2005 | - | $157.40 K(+5.9%) | $10.36 M(-21.5%) |
Jun 2005 | - | $148.60 K(-94.1%) | $13.20 M(-33.6%) |
Mar 2005 | - | $2.51 M(-66.7%) | $19.88 M(+9.9%) |
Dec 2004 | $18.09 M(+58.0%) | $7.54 M(+151.7%) | $18.09 M(+24.4%) |
Sep 2004 | - | $3.00 M(-56.1%) | $14.54 M(+0.8%) |
Jun 2004 | - | $6.83 M(+852.9%) | $14.42 M(+20.1%) |
Mar 2004 | - | $716.90 K(-82.0%) | $12.01 M(+4.8%) |
Dec 2003 | $11.45 M(+896.2%) | $3.99 M(+38.6%) | $11.45 M(+33.4%) |
Sep 2003 | - | $2.88 M(-34.8%) | $8.59 M(+49.9%) |
Jun 2003 | - | $4.42 M(+2633.5%) | $5.73 M(+336.9%) |
Mar 2003 | - | $161.60 K(-85.7%) | $1.31 M(+14.1%) |
Dec 2002 | $1.15 M(-19.5%) | $1.13 M(+5072.5%) | $1.15 M(+219.0%) |
Sep 2002 | - | $21.80 K(>+9900.0%) | $360.30 K(-44.4%) |
Jun 2002 | - | $0.00(0.0%) | $648.10 K(-39.5%) |
Mar 2002 | - | $0.00(-100.0%) | $1.07 M(-25.0%) |
Dec 2001 | $1.43 M(-87.2%) | $338.50 K(+9.3%) | $1.43 M(+26.2%) |
Sep 2001 | - | $309.60 K(-26.8%) | $1.13 M(-61.6%) |
Jun 2001 | - | $423.20 K(+18.8%) | $2.94 M(+25.4%) |
Mar 2001 | - | $356.20 K(+752.2%) | $2.35 M(-79.0%) |
Dec 2000 | $11.18 M(+222.4%) | $41.80 K(-98.0%) | $11.18 M(+0.4%) |
Sep 2000 | - | $2.12 M(-1327.0%) | $11.14 M(+23.5%) |
Jun 2000 | - | -$172.80 K(-101.9%) | $9.02 M(-1.9%) |
Mar 2000 | - | $9.19 M | $9.19 M |
Dec 1999 | $3.47 M | - | - |
FAQ
- What is Oncolytics Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for Oncolytics Biotech?
- What is Oncolytics Biotech annual CFF year-on-year change?
- What is the all time high quarterly CFF for Oncolytics Biotech?
- What is the all time high TTM CFF for Oncolytics Biotech?
What is Oncolytics Biotech annual cash flow from financing activities?
The current annual CFF of ONCY is $23.69 M
What is the all time high annual CFF for Oncolytics Biotech?
Oncolytics Biotech all-time high annual cash flow from financing activities is $32.62 M
What is Oncolytics Biotech annual CFF year-on-year change?
Over the past year, ONCY annual cash flow from financing activities has changed by +$14.31 M (+152.58%)
What is the all time high quarterly CFF for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly cash flow from financing activities is $30.08 M
What is the all time high TTM CFF for Oncolytics Biotech?
Oncolytics Biotech all-time high TTM cash flow from financing activities is $41.63 M